• 1953

    An established need

    At Harvard Medical School, Allen “Jack” Latham recognizes the need for improved blood processing systems.

  • 1968

    The keystone of future technology

    Building on the work of Dr. Edwin Cohn, Jack Latham invents a transparent, disposable centrifuge bowl, known as the Latham bowl.

  • 1971

    Haemonetics is founded

    Jack Latham founds Haemonetics in Natick, MA, dedicated to improving the safety and quality of blood supply.

    The dawn of a new age

    The Model 30 system is introduced, marking the beginning of the modern age of apheresis.

  • 1974

    A surgical first

    The Cell Saver® system is introduced as the first surgical washed blood salvage technology, soon to become the standard of care for hospitals.

  • 1978

    Continued growth, new space

    With new developments like Model 115 and Model 30-S, the company continues to grow, opening its Braintree, MA, facility at 400 Wood Road.

  • 1979

    Haemonetics goes public

    The company successfully completes an over-the-counter initial public offering, enabling future growth.

  • 1981

    First-of-its-kind development

    Cell Saver® 3 launches as the first system to automate surgical blood salvage.

    Becoming a global company

    The company opens its first international headquarters in Nyon, Switzerland.

  • 1984

    More plasma in less time

    Haemonetics launches the PCS® plasma collection system, significantly cutting the time needed to collect plasma and increasing donor safety.

    High-speed technology

    Cell Saver® 4, the first automated high-speed blood salvage technology, is launched.

    A private company

    A group of private investors, including present and former employees purchases the company.

  • 1986

    Used by the military

    The Department of Defense contracts for deployment of the Cell Saver® 4 and Model 115 systems at military installations and on ships worldwide.

  • 1987

    Inventor of the year

    Jack Latham is named “New England Inventor of the Year” by the Boston Patent Law Association.

  • 1990

    The facility in Leetsdale, PA, opens as a distribution center.

  • 1991

    A public company

    The company is taken public again, successfully completing an initial public offering (HAE) on the New York Stock Exchange.

  • 1992

    Global reach

    The company begins direct sales and service in Japan.

    A mobile system

    The company develops the MCS® mobile apheresis system, making it possible to provide blood component therapy to patients at blood banks.

  • 1993

    The PCS® 2 plasma collection system launches.

    The blow-molded version of the plasma collection bowl is introduced.

    A blow-molded bowl

    Manufacturing of the blow-molded bowl begins at the Leetsdale, PA, facility, the first time a blow-molded bowl is manufactured at a Haemonetics facility.

  • 1995

    The MCS®+ mobile platelet collection system launches.

    A new acquisition

    The company acquires the Intravenous Solutions manufacturing facility in Union, SC

  • 2001

    A new acquisition

    The company acquires a plasma collection bottle manufacturing facility and Fifth Dimension Information Systems.

    In the billions

    The company reaches the $1 billion market cap.

  • 2002

    Assisting the American Red Cross

    The American Red Cross launches a double red cell collection program using the MCS®+ 8150 system.

  • 2003

    The ACP® 215 system cell washing protocol is introduced.

  • 2004

    An improvement in plasma quality

    The company launches a proprietary plasma collection bowl that removes white blood cells from plasma without requiring an attached filtration device.

  • 2005

    New surgical developments

    The cardioPAT® surgical blood salvage system and the SmartSuction Harmony® surgical suction system are introduced.

  • 2008

    A new acquisition

    The company acquires Haemoscope and the TEG® 5000 hemostasis analyzer system.

  • 2009

    A new acquisition

    The company acquires Altivation Software and Neoteric Technology, both information management companies.

  • 2010

    A new acquisition

    The company acquires Global Med Technologies, Inc., a California-based medical information technology company.

  • 2011

    Cell Saver® Elite® autotransfusion system launches.

    Donor management

    NexGen DMS™ donor management software launches.

  • 2012

    A new acquisition

    The company acquires the blood collection, filtration, and processing product lines from Pall Corporation.

  • 2015

    Blood management

    The BloodTrack® HaemoBank® blood management solution is introduced.

    Predict and manage risk

    The TEG® 6s hemostasis analyzer and TEG Manager® software launch.

    Global expansion

    The Penang, Malaysia, manufacturing site holds its grand opening, while the Tijuana, Mexico, manufacturing facility expands.

  • 2017

    New enhancements

    Cell Saver® Elite®+ autologous blood recovery system launches with enhancements, including new design features and data connectivity capabilities.

    More productivity, more value

    The NexSys PCS® plasma collection device receives FDA 510(k) clearance.

  • 2018

    NexLynk DMS® software launches.

    Advancing technology

    YES® Technology (plasma yield enhancing solution) for NexSys PCS® receives FDA 510(k) clearance.

  • 2019

    New product indication

    TEG® 6s hemostasis analyzer receives FDA 510(k) clearance for use in U.S. adult trauma settings and begins shipment of TEG® 6s trauma cartridges.

    An international headquarters

    The company moves its global headquarters from Braintree, MA, into downtown Boston.

  • 2020

    Accelerating growth

    The company acquires intellectual property assets for the TEG® 6s hemostasis analyzer system.